Feed Preview


Hereditary Breast & Ovarian Cancer

Hereditary Breast & Ovarian Cancer diagram by undefined

Hereditary breast and ovarian cancer due to mutations in the brca1 and brca2 genes is the most common cause of hereditary forms of both breast and ovarian cancer. Here are the latest discoveries pertaining to these cancers.

Top 20 most recent papers
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology

Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: results from The BRCA1 and BRCA2 Cohort Consortium

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive OncologyDecember 2, 2019
Hong-Yan LiDavid E. Goldgar
Gynecologic Oncology

Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy

Gynecologic OncologyNovember 25, 2019
Mario M M LeitaoNadeem R Abu-Rustum
Scientific Reports

Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico

Scientific ReportsNovember 28, 2019
Julie DutilAlvaro N A Monteiro
Gynecologic Oncology

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Gynecologic OncologyNovember 29, 2019
Ignace VergoteRobert Michael Wenham
Gynecologic Oncology

Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection

Gynecologic OncologyNovember 28, 2019
Ajleeta SangtaniJamie N Bakkum-Gamez
Breast Cancer Research : BCR

Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC)

Breast Cancer Research : BCRNovember 28, 2019
Nur ZeinomarMary Beth Terry
Gynecologic Oncology

Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer

Gynecologic OncologyNovember 15, 2019
Sarah E TaylorKristin Kelley Zorn
Biochemical and Biophysical Research Communications

The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models

Biochemical and Biophysical Research CommunicationsNovember 28, 2019
Xinyu ChengXiao-Yun Shao
Gynecologic Oncology

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study

Gynecologic OncologyNovember 21, 2019
Phuong L. MaiMartee L Hensley
Gynecologic Oncology

Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention

Gynecologic OncologyNovember 25, 2019
Natalie E GriffinAndrea R Hagemann
Indian Journal of Cancer

Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective

Indian Journal of CancerNovember 1, 2019
Amit VermaVeda Padama Priya Selvakumar
Gynecologic Oncology

Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma

Gynecologic OncologyNovember 15, 2019
Derman BasaranMario M M Leitao
Gynecologic Oncology

Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277

Gynecologic OncologyNovember 16, 2019
Víctor Rodríguez-FreixinósAna Oaknin
Journal of Women's Health

Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer

Journal of Women's HealthNovember 27, 2019
Arnethea L SuttonVanessa B Sheppard
Gynecologic Oncology

Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs

Gynecologic OncologyNovember 25, 2019
Jvan CasarinAndrea Mariani
BMJ Open

Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study

BMJ OpenNovember 25, 2019
Amy Louise WinshipMartha Hickey
Gynecologic Oncology

Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients

Gynecologic OncologyNovember 19, 2019
Sou HiroseHiroshi Yoshida
Gynecologic Oncology

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer

Gynecologic OncologyNovember 19, 2019
Marina StasenkoKaren A Cadoo
Gynecologic Oncology

An update on fertility preservation strategies for women with cancer

Gynecologic OncologyNovember 28, 2019
Sukhkamal B Campbell, Terri Lynn Woodard
Gynecologic Oncology

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis

Gynecologic OncologyNovember 18, 2019
Cécile Le PageAnne-Marie Mes-Masson

See more papers from this feed

Related Feeds

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer: Risk Factors

Breast cancer is a multifactorial disease that is influenced by both environmental and genetic factors. Discover the latest research on the environmental and genetic risk factors for breast cancer here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Cervical Squamous Cell Carcinoma And Endocervical Adenocarcinoma

The cervix contains two types of cells and when cancer arises from squamous cells within the cervix it is cervical squamous cell carcinoma. The endocervix is located just above the body of the cervix and contains glandular cells. When cancer begins here it is called endocervical adenocarcinoma. Here is the latest research on these two types of cancers.

© 2019 Meta ULC. All rights reserved